A day after the Physics prize was given to two scientists for foundational work on machine learning, the Nobel Prize in ...

After putting forward preliminary clinical data earlier this year from its neuromodulation implant for reducing chronic ...

Illumina is welcoming a new addition to its DNA sequencing lineup, with a pair of accessible benchtop instruments that ...

Some six years after picking up Seattle’s Universal Cells for $102 million, Astellas Pharma is opening a second location for ...

Insitro has teamed up with Eli Lilly to help power programs into the clinic, tapping the Big Pharma for an option on ...

Boehringer Ingelheim has rolled into an alliance with undruggable target specialist Circle Pharma, putting together a package ...

InnoCare Pharma’s tyrosine kinase 2 (TYK2) inhibitor has hit the main goals of a phase 2 trial in China, sustaining the ...

With Kezar Life Sciences’ lupus plans up in the air while the company investigates patient deaths, Concentra Biosciences has ...

London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of ...

The Philadelphia-based biotech, founded and run by Jim Wilson, M.D., Ph.D., will receive up to $100 million from the Oswaldo ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...